iBio reported its financial results for Q1 FY2025 ended September 30, 2024, with no revenue and a reduced net loss of $4.0 million ($0.46 per share) compared to $5.1 million in the same period last year. R&D and G&A expenses decreased 20% to $4.1 million, reflecting the company's cash preservation strategy. The company maintained $11.3 million in cash and cash equivalents.The company made significant progress in its collaboration with AstralBio, advancing their joint myostatin program for cardiometabolic disease and obesity. They have manufactured and dosed a lead molecule in non-human primate studies, with potential early readouts expected in early 2025. Additionally, iBio strengthened its leadership team by appointing Kristi Sarno as Senior Vice President of Business Development, effective August 1, 2024.

iBio reported its financial results for Q1 FY2025 ended September 30, 2024, with no revenue and a reduced net loss of $4.0 million ($0.46 per share) compared to $5.1 million in the same period last year. R&D and G&A expenses decreased 20% to $4.1 million, reflecting the company's cash preservation strategy. The company maintained $11.3 million in cash and cash equivalents.The company made significant progress in its collaboration with AstralBio, advancing their joint myostatin program for cardiometabolic disease and obesity. They have manufactured and dosed a lead molecule in non-human primate studies, with potential early readouts expected in early 2025. Additionally, iBio strengthened its leadership team by appointing Kristi Sarno as Senior Vice President of Business Development, effective August 1, 2024.